Duraiswamy et al. also examined a dual PD-1 and CTLA-4 blockade and found that the regimen reversed CD8+ T cell dysfunction and produced tumor rejection in two-thirds of mice in an ID8-VEGF mouse model [101]. The gene discussed is CD8A; the disease is neoplasm.